Sort by
Refine Your Search
-
Employer
-
Field
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 20 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 20 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 20 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different
-
inhouse developed long-acting GLP-1 receptor agonist, Efsubaglutide alfa , has achieved regulatory approval and market access in China representing a major milestone in biologics innovation originating from
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 20 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 19 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different
-
State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University. | Spain | 8 days ago
research in focused ultrasound therapy, aiming to achieve breakthroughs in acoustic physics, ultrasound biology, multimodal imaging, intelligent treatment, and clinical big data. Our mission is to develop
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 20 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different
-
for three consecutive periods (2014-2018 and 2018-2022 and 2023-2026). ICN2 comprises 20 Research Groups, 7 Technical Development and Support Units and Facilities, and 2 Research Platforms, covering different